AI assistant
Allogene Therapeutics, Inc. — Director's Dealing 2021
Apr 2, 2021
33378_dirs_2021-04-02_a884cc9d-f506-4ee1-843f-9cc992e914e7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-03-26
Reporting Person: Chang David D (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-31 | Common Stock | G | 205778 | $0.00 | Acquired | 856044 | Indirect |
| 2020-08-31 | Common Stock | G | 205778 | $0.00 | Acquired | 856044 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2284869 | Direct |
| Common Stock | 1201108 | Indirect |
Footnotes
F1: Securities held in the name of the Chang 2006 Family Trust.
F2: On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary.
F3: Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F4: On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary.
F5: Securities held in the name of the RTC 2019 Trust dated October 1, 2019.